Alan Westwood has joined Matoke Holdings as the managing director of its pharmaceutical division, after spending 35 years at Bayer Health Care.
Westwood ended his time at Bayer as VP of global strategic marketing for anti-infectives. In his new role, he will be tasked with overseeing R&D of Matoke Pharma’s lead candidate, RO-101.
The biotech is looking to use its ‘reactive oxygen’ technology to create novel antimicrobial drug candidates. Its lead candidate uses synthetic biology to deliver reactive oxygen to chronic non-healing wounds, such as those involving multi-drug resistant pathogens.
Westwood said, “I’m delighted to take up the role of managing director of Matoke Pharma at this exciting time as it moves closer to achieving its ambition to bring a breakthrough antimicrobial medicinal product to market.”